1st Quarter - Report

KOUNTOUPES DENHAM CARR & REID, LLC for TEVA PHARMACEUTICALS USA, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$40,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2017 $40,000 Replaced
1st Quarter - Amendment Apr 20, 2017 $40,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to affordability and pricing of pharmaceuticals. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement. Issues related to H.R. 1628, the American Health Care Act.

Foreign entity interest: OrvetUK Teva Pharmaceuticals EuropeBV Teva Pharmaceutical Industries, Ltd.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1628 (115th)

Taxation/Internal Revenue Code TAX

Issues related to comprehensive tax reform and the proposed border adjustment tax.

Foreign entity interest: OrvetUK Teva Pharmaceuticals EuropeBV Teva Pharmaceutical Industries, Ltd.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

General education about the pharmaceutical industry. Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.

Foreign entity interest: OrvetUK Teva Pharmaceuticals EuropeBV Teva Pharmaceutical Industries, Ltd.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 771 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.